Cargando…

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker

BACKGROUND: Obtaining tissue for pancreatic carcinoma diagnosis and biomarker assessment to aid drug development is challenging. Circulating tumour cells (CTCs) may represent a potential biomarker to address these unmet needs. We compared prospectively the utility of two platforms for CTC enumeratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoja, L, Backen, A, Sloane, R, Menasce, L, Ryder, D, Krebs, M, Board, R, Clack, G, Hughes, A, Blackhall, F, Valle, J W, Dive, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273340/ https://www.ncbi.nlm.nih.gov/pubmed/22187035 http://dx.doi.org/10.1038/bjc.2011.545

Ejemplares similares

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
por: Greystoke, A, et al.
Publicado: (2012)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
por: Zhou, Cong, et al.
Publicado: (2016)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients
por: Stovold, R, et al.
Publicado: (2013)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas
por: Handra-Luca, A, et al.
Publicado: (2011)

Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours
por: Childs, Alexa, et al.
Publicado: (2016)

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
por: Couvelard, A, et al.
Publicado: (2005)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer
por: Dive, C, et al.
Publicado: (2010)

Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients
por: Wong, S C C, et al.
Publicado: (2011)

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer
por: Board, Ruth E, et al.
Publicado: (2008)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
por: Sadanandam, A, et al.
Publicado: (2012)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Heparan sulphate synthetic and editing enzymes in ovarian cancer
por: Backen, A C, et al.
Publicado: (2007)

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation
por: Skvortsova, T E, et al.
Publicado: (2006)

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy
por: Payne, R E, et al.
Publicado: (2012)

MYB is a novel regulator of pancreatic tumour growth and metastasis
por: Srivastava, Sanjeev K, et al.
Publicado: (2015)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope
por: Ntouroupi, T G, et al.
Publicado: (2008)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
por: Kawaguchi, T, et al.
Publicado: (2013)

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
por: Benoy, I H, et al.
Publicado: (2006)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
por: Lastraioli, E, et al.
Publicado: (2015)

Method validation of circulating tumour cell enumeration at low cell counts
por: Cummings, Jeffrey, et al.
Publicado: (2013)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma
por: Hamana, K, et al.
Publicado: (2005)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer
por: Morimura, R, et al.
Publicado: (2011)

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
por: Wolpin, B M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_qm5trm4ldgev78kpptl8uv6cdh